<scp>MiR</scp> ‐182‐3p targets <scp>TRF2</scp> and impairs tumor growth of triple‐negative breast cancer-Reference-Cited by-同舟云学术

MiR ‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer

Published:2022-11-25 Issue:1 Volume:15 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Dinami Roberto¹^ORCID,Pompili Luca¹,Petti Eleonora¹^ORCID,Porru Manuela¹^ORCID,D'Angelo Carmen¹,Di Vito Serena¹²,Rizzo Angela¹^ORCID,Campani Virginia³,De Rosa Giuseppe³,Bruna Alejandra⁴,Serra Violeta⁵^ORCID,Mano Miguel⁶⁷⁸^ORCID,Giacca Mauro⁸^ORCID,Leonetti Carlo¹,Ciliberto Gennaro⁹,Tarsounas Madalena¹⁰^ORCID,Stoppacciaro Antonella¹¹,Schoeftner Stefan¹²,Biroccio Annamaria¹^ORCID

Affiliation:

1. Translational Oncology Research Unit IRCCS—Regina Elena National Cancer Institute Rome Italy

2. Department of Ecological and Biological Sciences (DEB) University of Tuscia Viterbo Italy

3. Department of Pharmacy University Federico II of Naples Naples Italy

4. CRUK Cambridge Institute University of Cambridge Cambridge UK

5. Vall d'Hebron Institute of Oncology Barcelona Spain

6. Functional Genomics and RNA‐based Therapeutics Laboratory, Center for Neuroscience and Cell Biology (CNC) University of Coimbra Coimbra Portugal

7. Department of Life Sciences University of Coimbra Coimbra Portugal

8. King's College London, British Heart Foundation Centre of Research Excellence School of Cardiovascular Medicine & Sciences London UK

9. Scientific Direction IRCCS‐Regina Elena National Cancer Institute Rome Italy

10. Department of Oncology, Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology University of Oxford Oxford UK

11. Department of Clinical and Molecular Medicine, St. Andrea Hospital Sapienza University of Rome Rome Italy

12. Department of Life Sciences University of Trieste Trieste Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202216033

Reference60 articles.

1. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

2. Recent Advances in Liposomal-Based Anti-Inflammatory Therapy

3. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines

4. The Implications of Clonal Genome Evolution for Cancer Medicine

5. The Telomeric protein TRF2 regulates replication origin activity within Pericentromeric heterochromatin;Bauwens S;Life (Basel),2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting shelterin proteins for cancer therapy;Drug Discovery Today;2024-08

2. MicroRNAs role in telomere length maintenance and telomerase activity in tumor cells;Journal of Molecular Medicine;2024-07-23

3. Molecular insights into regulatory RNAs in the cellular machinery;Experimental & Molecular Medicine;2024-06-14

4. Lipid nanoparticles-based RNA therapies for breast cancer treatment;Drug Delivery and Translational Research;2024-06-03

5. Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer;Current Opinion in Pharmacology;2024-06